TY - JOUR
T1 - Imaging of C-X-C Motif Chemokine Receptor 4 Expression in 690 Patients with Solid or Hematologic Neoplasms Using 68Ga-Pentixafor PET
AU - Buck, Andreas K.
AU - Haug, Alexander
AU - Dreher, Niklas
AU - Lambertini, Alessandro
AU - Higuchi, Takahiro
AU - Lapa, Constantin
AU - Weich, Alexander
AU - Pomper, Martin G.
AU - Wester, Hans Jürgen
AU - Zehndner, Anja
AU - Schirbel, Andreas
AU - Samnick, Samuel
AU - Hacker, Marcus
AU - Pichler, Verena
AU - Hahner, Stefanie
AU - Fassnacht, Martin
AU - Einsele, Hermann
AU - Serfling, Sebastian E.
AU - Werner, Rudolf A.
N1 - Publisher Copyright:
COPYRIGHT © 2022 by the Society of Nuclear Medicine and Molecular Imaging.
PY - 2022/11/1
Y1 - 2022/11/1
N2 - In recent years, molecular imaging addressing the C-X-C motif chemokine receptor 4 (CXCR4) has increasingly been used in various clinical settings. Here, we aimed to assess radiopharmaceutical uptake and image contrast to determine the most relevant clinical applications for CXCR4-directed imaging. We also investigated the impact of specific activity on scan contrast. Methods: Patients (n 5 690) with a variety of neoplasms underwent a total of 777 PET/CT scans with
68Ga-Pentixa-for, serving as the CXCR4-specific radioligand. A semiquantitative target lesion analysis was conducted (providing SUV
max and target-to-blood pool ratio [TBR], defined as SUV
max [from target lesion] divided by SUV
mean [from blood pool]). The applied specific activity (in MBq/mg) was compared with semiquantitative assessments. Results: Of the 777 scans, 242 did not show discernible uptake in disease sites, leaving 535 PET scans (68.9%) for further analysis. Very high tracer uptake (SUV
max. 12) was found in multiple myeloma (n 5 113), followed by adrenocortical carcinoma (n 5 30), mantle cell lymphoma (n 5 20), adrenocortical adenoma (n 5 6), and small cell lung cancer (n 5 12). Providing information on image contrast, comparable results for TBR were recorded, with TBR (.8) in multiple myeloma, mantle cell lymphoma, and acute lymphoblastoid leukemia (n 5 6). When comparing specific activity with semiquantitative parameters, no significant correlation was found for SUV
max or TBR (P $ 0.612). Conclusion: In this large cohort,
68Ga-Pentixafor demonstrated high image contrast in a variety of neoplasms, particularly for hematologic malignancies, small cell lung cancer, and adrenocortical neoplasms. The present analysis may provide a roadmap for detecting patients who may benefit from CXCR4-targeted therapies.
AB - In recent years, molecular imaging addressing the C-X-C motif chemokine receptor 4 (CXCR4) has increasingly been used in various clinical settings. Here, we aimed to assess radiopharmaceutical uptake and image contrast to determine the most relevant clinical applications for CXCR4-directed imaging. We also investigated the impact of specific activity on scan contrast. Methods: Patients (n 5 690) with a variety of neoplasms underwent a total of 777 PET/CT scans with
68Ga-Pentixa-for, serving as the CXCR4-specific radioligand. A semiquantitative target lesion analysis was conducted (providing SUV
max and target-to-blood pool ratio [TBR], defined as SUV
max [from target lesion] divided by SUV
mean [from blood pool]). The applied specific activity (in MBq/mg) was compared with semiquantitative assessments. Results: Of the 777 scans, 242 did not show discernible uptake in disease sites, leaving 535 PET scans (68.9%) for further analysis. Very high tracer uptake (SUV
max. 12) was found in multiple myeloma (n 5 113), followed by adrenocortical carcinoma (n 5 30), mantle cell lymphoma (n 5 20), adrenocortical adenoma (n 5 6), and small cell lung cancer (n 5 12). Providing information on image contrast, comparable results for TBR were recorded, with TBR (.8) in multiple myeloma, mantle cell lymphoma, and acute lymphoblastoid leukemia (n 5 6). When comparing specific activity with semiquantitative parameters, no significant correlation was found for SUV
max or TBR (P $ 0.612). Conclusion: In this large cohort,
68Ga-Pentixafor demonstrated high image contrast in a variety of neoplasms, particularly for hematologic malignancies, small cell lung cancer, and adrenocortical neoplasms. The present analysis may provide a roadmap for detecting patients who may benefit from CXCR4-targeted therapies.
KW - 68Ga-Pentixafor
KW - C-X-C motif chemokine receptor 4
KW - CXCR4
KW - PET
KW - Ga-Pentixafor
UR - http://www.scopus.com/inward/record.url?scp=85131605131&partnerID=8YFLogxK
U2 - 10.2967/jnumed.121.263693
DO - 10.2967/jnumed.121.263693
M3 - Article
C2 - 35241482
AN - SCOPUS:85131605131
SN - 0161-5505
VL - 63
SP - 1687
EP - 1692
JO - Journal of nuclear medicine : official publication, Society of Nuclear Medicine
JF - Journal of nuclear medicine : official publication, Society of Nuclear Medicine
IS - 11
ER -